ArticleERJ open research2022
Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study.
Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 6 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Associations of the systemic immune-inflammation index and systemic inflammatory response index with chronic obstructive pulmonary disease: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Sarcopenia in end-stage lung disease patients: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Sarcopenia in idiopathic pulmonary fibrosis: an updated systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Chronic obstructive pulmonary disease as a risk factor for sarcopenia: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Prevalence of sarcopenia in patients with COPD through different musculature measurements: An updated meta-analysis and meta-regression.Frontiers in nutrition · 2023Pooled it
- Association between muscular atrophy and mortality risk in patients with COPD: a systematic review.Therapeutic advances in respiratory diseasePooled it
- Pathological changes and therapeutic strategies for sarcopenia.EFORT open reviews · 2026Review
- Association Between Systemic Immune-Inflammation Index and Thyroid Function: A Cross-Sectional Population-Based Study.International journal of endocrinology · 2026Article
- Elevated Inflammatory Burden Index Is Association With Increased Sarcopenia: A Population-Based Study.Mediators of inflammation · 2026Article
- Research Progress of Sarcopenia Index in Chronic Obstructive Pulmonary Disease: A Review.Cureus · 2025Review
- Role of Systemic Inflammatory Markers in the Differential Diagnosis of Organizing Pneumonia and Lung Cancer.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Airway Candida diversity in COPD patients and its differential stimulatory effects on lung inflammation in mice.BMC pulmonary medicine · 2025Article
- Comorbidity profiles in chronic obstructive pulmonary disease: a multicohort study.ERJ open research · 2025Article
- MG53 deficiency mediated skeletal muscle dysfunction in chronic obstructive pulmonary disease via impairing mitochondrial fission.Redox biology · 2025Article
- Relationship between systemic immune response index (SIRI) and COPD: a cross-sectional study based on NHANES 2007-2012.Scientific reports · 2025Article
- Association between monocyte-high-density lipoprotein cholesterol ratio and mortality in a population with asthma: a cohort study.Lipids in health and disease · 2025Article
- Association between systemic immune-inflammation index and the risk of all-cause, cancer and non-cancer mortality in the general population: results from national health and nutrition examination survey 2005-2018.BMC public health · 2025Article
- Joint association of systemic immune-inflammation index and phenotypic age acceleration with chronic respiratory disease: a cross-sectional study.BMC public health · 2025Article
- Association of relative fat mass with asthma: inflammatory markers as potential mediators.Lipids in health and disease · 2025Article
- AORI-HAP: a multidimensional risk index to predict in-hospital adverse outcomes in asthma exacerbations.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing evidence suggests that sarcopenia and a higher systemic immune-inflammation index (SII) are linked with morbidity in patients with COPD. However, whether these two conditions contribute to all-cause mortality in middle-aged and older patients with COPD or asthma is unclear. Therefore, we investigated the association between sarcopenia, SII, COPD or asthma and all-cause mortality in a large-scale population-based setting.
methodsBetween 2009 and 2014, 4482 participants (aged >55 years; 57.3% female) from the population-based Rotterdam Study were included. COPD and asthma patients were diagnosed clinically and based on spirometry. Six study groups were defined according to the presence or absence of COPD or asthma and sarcopenia. Cox regression models were used to assess all-cause mortality in the study groups, adjusted for sex, age, body mass index, SII, smoking, oral corticosteroid use and comorbidities. In addition, all participants were categorised into sex-specific quartiles of SII, and mortality in these groups was compared.
resultsOver a median follow-up of 6.1 years (interquartile range 5.0-7.2 years), 466 (10.4%) persons died. Independent of the presence of sarcopenia, participants with COPD had a higher risk of all-cause mortality (hazard ratio (HR) 2.13, 95% CI 1.46-3.12 and HR 1.70, 95% CI 1.32-2.18 for those with and without sarcopenia, respectively). Compared to lower SII levels, higher SII levels increased mortality risk even in people without sarcopenia, COPD or asthma.
conclusionMiddle-aged and older people with COPD, higher SII levels or sarcopenia had an independently increased mortality risk. Our study suggests prognostic usefulness of routinely evaluating sarcopenia and SII in older people with COPD or asthma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.